Characteristics and relative survivin protein levels of AML and normal CD34+ samples analyzed
| AML patient no. . | FAB . | BM blast (%) . | Cytogenetics . | Relativesurvivin level . |
|---|---|---|---|---|
| 1 | M2 | 77 | 47,XY,+19[18] | 0.28 |
| 2 | M2 | 97 | 46,XY[20] | 0.76 |
| 3 | M5B | 73 | 46,XX[25] | 0.41 |
| 4 | M1 | 80 | 46,XX,inv(9)(p11q12)[19] | 1.17 |
| 5 | M1 | 78 | 46,XX,inv(16) (p13q22), idic(22)(q11)[20] | 0.29 |
| 6 | M5B | 89 | 46,XY[29] | 0.36 |
| 7 | M1 | 86.6 | 46,XY,iso17(q10)[8] 46,XY[12] | 0.73 |
| 8 | M5 | 71 | 46,XY[30] | 0.16 |
| 9 | M1 | 90.4 | 46,XX[20] | 0.67 |
| 10 | AML-prior | 43 | 46,XX[19] | 0.23 |
| 11 | M1 | 51 | 45,XY,−7[20] | 0 |
| 12 | M1 | 51 | 47,XY,+4[18] | 0.12 |
| 48,XY,+4,+8[1] | ||||
| 13 | M2 | 71 | 46,XY,add(2)(q37),−5,−22, +2mar[20] | 0.25 |
| 14 | M1 | 89 | 47,XY,+8[16] | 0.55 |
| 15 | M2 | 76 | 46,XY[20] | 0.78 |
| 16 | M1 | 73 | 40-4,XY,add(1)(p36), del(1)(q22),−2,−4,−5, add(5) (q35),−7,−11, −12,−12,−13,−15, add(16)(p13),−17, add(19)(q13),−A | 0.21 |
| 17* | M3-microgranular type | 78 | 46,XY,inv(9)(p11q12), t(15;17)(q22;q21)[20] | 0 |
| 18 | M5A | 88 | 47,XY,+11[9] 48,XY,+11, +13[10] | 0.75 |
| 46,XY[1] | ||||
| Normal CD34+ | ||||
| 1 | BM | 0.25 | ||
| 2 | BM | 0.09 | ||
| 3 | BM | 0.23 | ||
| 4 | BM | 0 | ||
| 5 | PB | 0 | ||
| 6 | PB | 0 | ||
| 7 | PB | 0 |
| AML patient no. . | FAB . | BM blast (%) . | Cytogenetics . | Relativesurvivin level . |
|---|---|---|---|---|
| 1 | M2 | 77 | 47,XY,+19[18] | 0.28 |
| 2 | M2 | 97 | 46,XY[20] | 0.76 |
| 3 | M5B | 73 | 46,XX[25] | 0.41 |
| 4 | M1 | 80 | 46,XX,inv(9)(p11q12)[19] | 1.17 |
| 5 | M1 | 78 | 46,XX,inv(16) (p13q22), idic(22)(q11)[20] | 0.29 |
| 6 | M5B | 89 | 46,XY[29] | 0.36 |
| 7 | M1 | 86.6 | 46,XY,iso17(q10)[8] 46,XY[12] | 0.73 |
| 8 | M5 | 71 | 46,XY[30] | 0.16 |
| 9 | M1 | 90.4 | 46,XX[20] | 0.67 |
| 10 | AML-prior | 43 | 46,XX[19] | 0.23 |
| 11 | M1 | 51 | 45,XY,−7[20] | 0 |
| 12 | M1 | 51 | 47,XY,+4[18] | 0.12 |
| 48,XY,+4,+8[1] | ||||
| 13 | M2 | 71 | 46,XY,add(2)(q37),−5,−22, +2mar[20] | 0.25 |
| 14 | M1 | 89 | 47,XY,+8[16] | 0.55 |
| 15 | M2 | 76 | 46,XY[20] | 0.78 |
| 16 | M1 | 73 | 40-4,XY,add(1)(p36), del(1)(q22),−2,−4,−5, add(5) (q35),−7,−11, −12,−12,−13,−15, add(16)(p13),−17, add(19)(q13),−A | 0.21 |
| 17* | M3-microgranular type | 78 | 46,XY,inv(9)(p11q12), t(15;17)(q22;q21)[20] | 0 |
| 18 | M5A | 88 | 47,XY,+11[9] 48,XY,+11, +13[10] | 0.75 |
| 46,XY[1] | ||||
| Normal CD34+ | ||||
| 1 | BM | 0.25 | ||
| 2 | BM | 0.09 | ||
| 3 | BM | 0.23 | ||
| 4 | BM | 0 | ||
| 5 | PB | 0 | ||
| 6 | PB | 0 | ||
| 7 | PB | 0 |
FAB, French-American-British classification; BM blast (%), percentage of leukemic blasts before Ficoll-Hypaque separation; relative survivin level, ratio of survivin/actin relative to that of OCI-AML3.
77% promyeloblast, 1% blast.